Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells

Cancer Chemother Pharmacol. 1994;33(6):504-8. doi: 10.1007/BF00686509.

Abstract

Previous studies have clearly demonstrated that polyisobutylcyanoacrylate (PIBCA) doxorubicin-loaded nanoparticles (NS-Dox PIBCA) can overcome the resistance of P388/ADR cells. In the present paper, we found that overcoming multidrug resistance with the aid of doxorubicin (Dox) loaded onto these nanoparticles was associated with an increased intracellular drug content. Indeed, after a 6-h incubation period, the amount of cell-associated drug was 5 times higher when the cells were incubated with NS-Dox PIBCA as compared with free Dox. Further experiments, such as uptake studies in the presence of cytochalasin B or efflux studies, indicated a possible mechanism of nanoparticle/cell interaction. These results suggested that nanoparticles did not enter the cells by an endocytic process, in contrast to a previous hypothesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Doxorubicin / administration & dosage
  • Doxorubicin / metabolism*
  • Drug Carriers
  • Drug Resistance
  • Leukemia P388 / metabolism*
  • Mice
  • Microspheres
  • Tumor Cells, Cultured

Substances

  • Drug Carriers
  • Doxorubicin